Monte Rosa Therapeutics (GLUE) Return on Capital Employed (2023 - 2025)
Historic Return on Capital Employed for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to 0.02%.
- Monte Rosa Therapeutics' Return on Capital Employed rose 4700.0% to 0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02%, marking a year-over-year increase of 4700.0%. This contributed to the annual value of 0.38% for FY2024, which is N/A changed from last year.
- Latest data reveals that Monte Rosa Therapeutics reported Return on Capital Employed of 0.02% as of Q3 2025, which was up 4700.0% from 0.04% recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' Return on Capital Employed peaked at 0.04% during Q2 2025, and registered a low of 0.62% during Q4 2023.
- In the last 3 years, Monte Rosa Therapeutics' Return on Capital Employed had a median value of 0.41% in 2024 and averaged 0.31%.
- Per our database at Business Quant, Monte Rosa Therapeutics' Return on Capital Employed surged by 2500bps in 2024 and then soared by 5800bps in 2025.
- Quarter analysis of 3 years shows Monte Rosa Therapeutics' Return on Capital Employed stood at 0.62% in 2023, then soared by 40bps to 0.37% in 2024, then soared by 107bps to 0.02% in 2025.
- Its last three reported values are 0.02% in Q3 2025, 0.04% for Q2 2025, and 0.01% during Q1 2025.